Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The EPR effect in human tumors: a critical re-evaluation of a nanomedicine dogma and a call for new targeting paradigms.

Nanomedicine (London, England)·2026
Same author

Neuroprotection Through Nature: The Role of Bioactive Phytocompounds in Alzheimer's and Parkinson's Disease.

Current neurovascular research·2026
Same author

Nutritional Composition, Therapeutic Benefits, and Functional Food Potential of <i>Coleus amboinicus</i>: A Comprehensive Review.

Food science & nutrition·2026
Same author

Interplay of Genetic and Biomarker Signatures in Oxidative Stress and Inflammation: Advancing Parkinson's Disease Research Through Emerging Omics Technologies.

Current neurovascular research·2026
Same author

Targeting α-Synuclein Aggregation in Parkinson's Disease: A Narrative Review of Current Gene Therapy Strategies.

Current neuropharmacology·2026
Same author

Innovative Drug Delivery Strategies for Enhanced Treatment of Antimicrobial Resistance.

Current drug delivery·2026

関連する実験動画

Updated: Sep 9, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

心筋線維症の治療目標:現在のアプローチと新興アプローチの包括的なレビュー

Ankita Wal1, Anurag Rawat2, Rakesh Verma3

  • 1Department of Pharmacy, PSIT-Pranveer Singh Institute of Technology, NH19 Kanpur Agra highway Bhauti Kanpur, Kanpur, India.

Cardiovascular & hematological disorders drug targets
|September 5, 2025
PubMed
まとめ

心筋線維症は 心不全に大きく寄与し 現在の治療法は不十分です 多様な分子メカニズムを標的とした 多面的な治療アプローチは 患者の治療結果を改善するために不可欠です

キーワード:
RAAS阻害剤についてSGLT2阻害剤TGF-β 阻害剤マトリックスメタルプロテインゼ心筋線維症

さらに関連する動画

Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts
10:45

Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts

Published on: March 12, 2020

16.2K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K

関連する実験動画

Last Updated: Sep 9, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K
Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts
10:45

Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts

Published on: March 12, 2020

16.2K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K

科学分野:

  • 心血管医学
  • 分子生物学
  • 薬理学について

背景:

  • 心血管疾患 (CVD) は,世界の死亡原因の1位です.
  • 心筋線維症は心臓機能不全や心不全の発症の重要な要因である.
  • CVDによる若年層の死亡率が増加しているため,高度な研究が必要である.

研究 の 目的:

  • 心筋線維症の原因である 分子メカニズムの見直し
  • 心筋線維症の現在および新興の治療戦略を探求する.
  • 心筋線維症とその合併症の治療に関するデータを統合する.

主な方法:

  • PubMed,Scopus,Elsevier,およびClinicalTrials.govの総合的な文献レビューを掲載しています.
  • 心筋線維症のメカニズムと治療法に関するピアレビューされた英語の研究を含む.
  • 前臨床試験と臨床試験のデータの質的合成

主要な成果:

  • 心筋線維症は 病理的な状態から生じます 缺血や高脂血症などです
  • 伝統的な治療法 (RAAS阻害剤,β阻害剤) は症状を緩和しますが,線維症の進行を止めることはできません.
  • 複数の分子経路が関与し 新しい治療目標を提供しています

結論:

  • モノセラピーは,心筋線維症の複雑な病理生理学に対処するのに不十分です.
  • 新興療法には,抗TGF-β剤,SGLT2阻害剤,MMP阻害剤,再生アプローチ (幹細胞,遺伝子療法) が含まれる.
  • 様々な分子メカニズムを標的とした多面的な治療戦略は,心不全の臨床結果の改善に不可欠です.